Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.43 |
| ▸ | HTR3A | P46098 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005492 | 0.95 | CHRNA7 (0.46) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| Fumaric Acid SCHEMBL5420260 | 0.88 | CHRNA7 (0.43) | CHRNA7HTR3A | |
| Fumaric Acid SCHEMBL5420255 | 0.88 | CHRNA7 (0.43) | CHRNA7HTR3A | |
| SCHEMBL5403328 | 0.86 | HTR3A (0.42) | CHRNA7HTR3AGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5651641 | 0.85 | HTR3A (0.41) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL1542568 | 0.78 | HTR3A (0.46) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL13444722 | 0.78 | CHRNA7 (0.59) | CHRNA7HTR3AGAA | |
| SCHEMBL3928547 | 0.78 | CHRNA7 (0.59) | CHRNA7HTR3AGAA | |
| Hydrochloric Acid SCHEMBL5649732 | 0.77 | HTR3A (0.44) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL5400969 | 0.77 | CHRNA7 (0.55) | CHRNA7HTR3AGAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309699-B2 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-12-18 | — | — | US | claimed |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | JI JIANGUO | 2007-11-29 | — | — | US | claimed |
| JP-2007515485-A | — | — | 2007-06-14 | — | — | JP | claimed |
| EP-1699785-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005066166-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | claimed |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7309699-B2 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | JI JIANGUO | 2007-11-29 | — | — | US | disclosed |
| EP-1699785-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066166-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | CHRNA7, CHRNA9, CHRNA1 | CHRNA7 1/4885HTR3A 123/4885BRAF 4727/4885 |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | CHRNA7, CHRNA9, CHRNA1 | CHRNA7 1/4885HTR3A 123/4885BRAF 4727/4885 |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | CHRNA9, CHRNA7, CHRNA1 | CHRNA7 2/4885HTR3A 156/4885BRAF 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.